Sympathetic nervous system function in renal hypertension

Current Hypertension Reports

Volumn 4, Issue 3, 2002, Pages 229-236

  Tuncel, Meryem ^a   Augustyniak, Robert ^a   Zhang, Weiguo ^a   Toto, Robert D ^a   Victor, Ronald G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC SYSTEM; ANIMAL; CROSS-SECTIONAL STUDY; HUMAN; PATHOPHYSIOLOGY; RENOVASCULAR HYPERTENSION; REVIEW; VASCULARIZATION;

ANIMALS; CROSS-SECTIONAL STUDIES; HUMANS; HYPERTENSION, RENAL; SYMPATHETIC NERVOUS SYSTEM;

EID: 0036616016     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-002-0012-7     Document Type: Article

References (43)

1. United States Renal Data System: 1999 Annual Data Report. Bethesda: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1999.
2. Levey AS: Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? Am J Kidney Dis 1998, 32: S5-S13.
3. Cheigh JS, Milite C, Sullivan JF, et al.: Hypertension is not adequately controlled in hemodialysis patients. Am J Kidney Dis 1992, 19: 453-459.
4. Salem MM: Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 1995, 26: 461-468.
5. Agodoa LY, Appel L, Bakris GL, et al.: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285: 2719-2728.
6. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345: 851-860.
7. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345: 861-869.
8. Lilley JJ, Golden J, Stone RA: Adrenergic regulation of blood pressure in chronic renal failure. J Clin Invest 1976, 57: 1190-1200.
9. Nies AS, Robertson D, Stone WJ: Hemodialysis hypotension is not the result of uremic peripheral autonomic neuropathy. J Lab Clin Med 1979, 94: 395-402.
10. Henrich WL, Katz FH, Molinoff PB, Schrier RW: Competitive effects of hypokalemia and volume depletion on plasma renin activity, aldosterone and catecholamine concentrations in hemodialysis patients. Kidney Int 1977, 12: 279-284.
11. Baumgart P, Walger P, Gerke M, et al.: Nocturnal hypertension in renal failure, haemodialysis and after renal transplantation. J Hypertens Suppl 1989, 7: S70-S71.
12. Timio M, Lolli S, Verdura C, et al.: Circadian blood pressure changes in patients with chronic renal insufficiency: a prospective study. Ren Fail 1993, 15: 231-237.
13. Timio M, Venanzi S, Lolli S, et al.: "Non-dipper" hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol 1995, 43: 382-387.
14. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG: Somatosen-sory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev 1979, 59: 919-957.
15. Converse RL Jr, Jacobsen TN, Toto RD, et al.: Sympathetic over-activity in patients with chronic renal failure. N Engl J Med 1992, 327: 1912-1918.
16. Converse RL Jr, Jacobsen TN, Jost CM, et al.: Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest 1992, 90: 1657-1665.
17. DiBona GF, Kopp UC: Neural control of renal function. Physiol Rev 1997, 77: 75-197.
18. Katholi RE, McCann WP, Woods WT: Intrarenal adenosine produces hypertension via renal nerves in the one-kidney, one clip rat. Hypertension 1985, 7: I88-I93.
19. Recordati G, Moss NG, Genovesi S, Rogenes P: Renal chemore-ceptors. J Auton Nerv Syst 1981, 3: 237-251.
20. Katholi RE, Winternitz SR, Oparil S: Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat. J Clin Invest 1982, 69: 55-62.
21. Wyss JM, Aboukarsh N, Oparil S: Sensory denervation of the kidney attenuates renovascular hypertension in the rat. Am J Physiol 1986, 250: H82-H86.
22. Katholi RE: Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol 1983, 245: F1-F14.
23. Zhang W, Li JL, Hosaka M, et al.: Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings. Proc Natl Acad Sci U S A 2000, 97: 9765-9770.
24. Johansson M, Elam M, Rundqvist B, et al.: Increased sympathetic nerve activity in renovascular hypertension. Circulation 1999, 99: 2537-2542.
25. Kraus MA, Hamburger RJ: Sleep apnea in renal failure. Adv Perit Dial 1997, 13: 88-92.
26. Hanly PJ, Pierratos A: Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001, 344: 102-107.
27. O'Sullivan DA, McCarthy JT, Kumar R, Williams AW: Improved biochemical variables, nutrient intake, and hormonal factors in slow nocturnal hemodialysis: a pilot study. Mayo Clin Proc 1998, 73: 1035-1045.
28. Pierratos A: Nocturnal home haemodialysis: an update on a 5-year experience. Nephrol Dial Transplant 1999, 14: 2835-2840.
29. Nordfors L, Lonnqvist F, Heimburger O, et al.: Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 1998, 54: 1267-1275.
30. Haynes WG, Morgan DA, Walsh SA, et al.: Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997, 10 0: 270-278.
31. Hall JE, Hildebrandt DA, Kuo J: Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001, 14: 103S-115S.
32. Thomas GD, Zhang W, Victor RG: Nitric oxide deficiency as a cause of clinical hypertension: promising new drug targets for refractory hypertension. JAMA 2001, 285: 2055-2057.
33. Vallance P, Leone A, Calver A, et al.: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339: 572-575.
34. Campese VM, Kogosov E, Koss M: Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995, 26: 861-865.
35. Campese VM, Kogosov E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995, 25: 878-882.
36. Frohlich ED, Tarazi RC, Dustan HP: Re-examination of the hemodynamics of hypertension. Am J Med Sci 1969, 257: 9-23.
37. Lazarus JM, Hampers C, Merrill JP: Hypertension in chronic renal failure. Treatment with hemodialysis and nephrectomy. Arch Intern Med 1974, 133: 1059-1066.
38. Lazarus JM, Hampers CL, Bennett AH, et al.: Urgent bilateral nephrectomy for severe hypertension. Ann Intern Med 1972, 76: 733-739.
39. DiBona GF: Central sympathoexcitatory actions of angiotensin II: role of type 1 angiotensin II receptors. J Am Soc Nephrol 1999, 10(Suppl 11): S90-S94.
40. Matsukawa S, Reid IA: Role of the area postrema in the modulation of the baroreflex control of heart rate by angiotensin II. Circ Res 1990, 67: 1462-1473.
41. Ligtenberg G, Blankestijn PJ, Oey PL, et al.: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999, 340: 1321-1328.
42. Amann K, Rump LC, Simonaviciene A, et al.: Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000, 11: 1469-1478.
43. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317: 713-720.